⚡️ What’s new in healthcare this week?

RCM’s 2026 reality check, Hims’ $1.15B global expansion, wearables and parenting perks go mainstream, fresh AI mega-funds close, a Danish neuro startup rises, and agentic AI hits scale ahead of ViVE

Nul is a digital treatment program for alcohol use disorder that combines prescription medication with behavioral support. The platform connects members with licensed clinicians who can prescribe FDA-approved medications to reduce cravings, alongside coaching and structured guidance delivered remotely. By focusing on evidence-based medical treatment rather than abstinence-only models, Nul aims to make alcohol recovery more accessible, private, and personalized.

---

Hey there Insider,

Hope you had a fantastic week!

Here’s your must-read weekly roundup of the latest news and developments in the digital healthcare sector! 👇🏼

1. Inside RCM: Payer pressure, visibility gaps, and the reality of 2026.

2. Hims & Hers buys Australian digital health firm for $1.15bn.

3. Amazfit debuts T-Rex Ultra 2 watch with biotracking, 30-day battery.

4. Carrot expands parenting benefits, adding on-demand pediatric telemedicine with Blueberry Pediatrics.

5. Frist Cressey Ventures closes $425M fund IV and more investment news.

6. Female-led Danish startup Hemi Health raises €4 million to expand migraine and concussion care internationally.

7. Athenahealth launches agentic patient communication tools across its provider network, which serves one in five Americans.

8. Merck–Mayo Clinic partnership aligns clinical data with AI Drug Discovery.

9. Flatiron launches first-of-its-kind AI-powered global prostate cancer datasets.

10. February 22-25 | Los Angeles, CA
    ViVE 2026 - We’ll be there!

11. March 2nd | Online
    Longevity + AI: Scaling personalization into healthcare infrastructure.

Until next week, stay connected!

Digital Health Insider.